Facts and fiction in inhalation therapy

Italian Journal of Pediatrics

Volumn 29, Issue 1, 2003, Pages 39-43

  Tiddens, Harm A W M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Children; Inhalation therapy; Respiratory diseases

Indexed keywords

ACETYLCYSTEINE; DORNASE ALFA; NEOMYCIN; SODIUM CHLORIDE; TOBRAMYCIN;

AEROSOL; CHILD; DRUG DELIVERY SYSTEM; DRY POWDER; HUMAN; METERED DOSE INHALER; NEBULIZATION; NEBULIZER; PARTICLE SIZE; REVIEW;

EID: 0037318779     PISSN: 17208424     EISSN: 18247288     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Kuwano K, Bosken CH, Pare PD, Bai TR, Wiggs BR, Hogg JC. Small airways dimensions in asthma and chronic obstructive pulmonary disease. Am Rev Respir Dis 1993;148:1220-5.
2. Tiddens HAWM, Pare PD, Hogg JC, Hop WCJ, Lambert R, de Jongste JC. Cartilaginous airway dimensions and airflow obstruction in human lungs. Am J Respir Crit Care Med 1995;152:260-6.
3. Tiddens HAWM, Koopman LP, Lambert RK, Elliott WM, Hop WCJ, van der Mark TW, et al. Cartilaginous airway wall dimensions and airway resistance in cystic fibrosis lungs. Eur Respir J 2000;15:735-42.
4. Tiddens HAWM. Respiratory distress in BPD: from morphology to therapy. Ital J Pediatr 2001;27:514-5.
5. Janssens HM, Krijgsman AM, Verbraak AFM, Hop WCJ, de Jongste JC, Tiddens HAWM. Fine particle size improves lung deposition of inhaled steroids in infants: a study in an upper airway model. Am J Respir Crit Care Med 2000;161(Suppl.):A32.
6. Laube BL, Jashnani R, Dalby RN, Zeitlin PL. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. Chest 2000;118:1069-76.
7. Mallol J, Rattray S, Walker G, Cook D, Robertson CF. Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol 1996;21:276-81.
8. Le Souef PN, and Devadason SG. Lung dose of inhaled drugs in children with acute asthma. J Aerosol Med. 2002;15:347-9.
9. Tsuda A, Rogers RA, Hydon PE, Butler JP. Chaotic mixing deep in the lung. Proc Natl Acad Sci USA 2002;99:10173-8.
10. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998;12:1346-53.
11. Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B, Diot P, et al. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J 2001;18:228-42.
12. Everard ML, Clark AR, Milner AD. Drug delivery from holding chambers with attached facemask. Archives on Disease in Childhood 1992;67:580-5.
13. Chua HL, Collis GG, Newbury AM, Chan K, Bower GD, Sly PD, et al. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J 1994;7:2185-91.
14. Struycken VHJ, Tiddens HAWM, van den Broek ET, Dzoljic-Danilovic G, van der Velden AJCM, de Jongste JC. Problemen met gebruik, reiniging en onderhoud van vernevelapparatuur in de thuissituatie. Ned Tijdschr Geneeskd 1996;140:654-8.
15. Rosenfeld M, Emerson J, Astley S, Joy P, Williams-Warren J, Standaert TA, et al. Home nebulizer use among patients with cystic fibrosis. J Pediatr 1998;132:125-31.
16. Vassal S, Taamma R, Marty N, Sardet A, d'athis P, Bremont F, et al. Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis. Am J Infect Control 2000;28:347-51.
17. Cates CJ, Rowe BH. Holding chambers versus nebulizers for beta-agonist treatment of acute asthma. Cochrane database Syst Rev 2001;2:CD001491.
18. Kosorok MR, Jalaluddin M, Farrell PM, Shen G, Colby CE, Laxova A, et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cysticfibrosis. Pediatr Pulmonol 1998;26:81-8.
19. Wildhaber JH, Devadason SG, Eber E, Hayden MJ, Everard ML, Summers QA, et al. Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax 1996;51:985-8.
20. Wildhaber JH, Devadason SG, Hayden MJ, James R, Dufty AP, Fox RA, et al. Electrostatic charge on a plastic spacer influences the delivery of salbutamol. Eur Respir J 1996;9:1943-6.
21. Janssens HM, Heijnen EM, de Jong VM, Hop WC, Holland WP, de Jongste JC, et al. Aerosol delivery from spacers in wheezy infants: a daily life study. Eur Respir J 2000;16:850-6.
22. Esposito-Festen JE, Verbraak T, Holland WP, Tiddens HAWM. Efficiency of aerosol delivery by pMDI-spacer to young children strongly depends on optimal seal of the facemask. Am J Respir Crit Care Med 2002;165:A188.
23. Janssens HM, de Jongste JC, Tiddens HAWM. Five fold reduction in lung dose from a static spacer with HFA-Fluticasone: a study in an infant upper airway model. International Paediatric Respiratory and Allergy Congress, Prague, 2001.
24. Janssens HM, Heijnen EM, de Jong VM, Hop WC, Holland WP, de Jongste JC, et al. Aerosol delivery from spacers in wheezy infants: a daily life study. Eur Respir J 2000;16:850-6.
25. Kamin WE, Genz T, Roeder S, Scheuch G, Trammer T, Juenemann R, et al. Mass output and particle size distribution of glucocorticosteroids emitted from different inhalation devices depending on various inspiratory parameters. J Aerosol Med 2002;15:65-73.
26. Devadason SG, Everard ML, MacEarlan C, Roller C, Summers QA, Swift P, et al. Lung deposition from the Turbuhaler in children with cystic fibrosis. Eur Respir J 1997;10:2023-8.
27. Bisgaard H, Klug B, Sumby BS, Burnell PK. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998;11:1111-5.
28. Nielsen KG, Auk IL, Bojsen K, Ifversen M, Klug B, Bisgaard H. Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children. Eur Respir J 1998;11:350.